![Hani N. Sabbah](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Frank A. Ahmann | M | - |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | - |
Christian S. Eversull | M | - |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | - |
Andrew Justin Stewart Coats | M | - |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | - |
J. Alan Crunkleton | M | - |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | - |
Juliana Elstad | F | 47 |
MateraCor, Inc.
![]() MateraCor, Inc. Medical SpecialtiesHealth Technology Part of BioVentrix, Inc., MateraCor, Inc. is a southern-based biotech start-up that develops novel approaches to prevent progression and reverse heart failure. The company is based in Aliso Viejo, CA. The company's lead product, Trans-Catheter Myocardial Restoration (TCMR), is an investigational device that consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction (HFREF). The CEO of the company is Frank A. Ahmann. MateraCor was acquired by BioVentrix, Inc. on January 27, 2022. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 5 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Hani N. Sabbah
- Réseau Personnel